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Abstract
Background: In physiological conditions, it is postulated that neurons control microglial reactivity through
a series of inhibitory mechanisms, involving either cell contact-dependent, soluble-factor-dependent or
neurotransmitter-associated pathways. In the current study, we focus on CD200R1, a microglial receptor involved
in one of these cell contact-dependent mechanisms. CD200R1 activation by its ligand, CD200 (mainly expressed by
neurons in the central nervous system),is postulated to inhibit the pro-inflammatory phenotype of microglial cells,
while alterations in CD200-CD200R1 signalling potentiate this phenotype. Little is known about the regulation of
CD200R1 expression in microglia or possible alterations in the presence of pro-inflammatory stimuli.
Methods: Murine primary microglial cultures, mixed glial cultures from wild-type and CCAAT/enhancer binding
protein β (C/EBPβ)-deficient mice, and the BV2 murine cell line overexpressing C/EBPβ were used to study the
involvement of C/EBPβ transcription factor in the regulation of CD200R1 expression in response to a
proinflammatory stimulus (lipopolysaccharide (LPS)). Binding of C/EBPβ to the CD200R1 promoter was determined
by quantitative chromatin immunoprecipitation (qChIP). The involvement of histone deacetylase 1 in the control
of CD200R1 expression by C/EBPβ was also determined by co-immunoprecipitation and qChIP.
Results: LPS treatment induced a decrease in CD200R1 mRNA and protein expression in microglial cells, an effect
that was not observed in the absence of C/EBPβ. C/EBPβ overexpression in BV2 cells resulted in a decrease in
basal CD200R1 mRNA and protein expression. In addition, C/EBPβ binding to the CD200R1 promoter was
observed in LPS-treated but not in control glial cells, and also in control BV2 cells overexpressing C/EBPβ. Finally,
we observed that histone deacetylase 1 co-immunoprecipitated with C/EBPβ and showed binding to a C/EBPβ
consensus sequence of the CD200R1 promoter in LPS-treated glial cells. Moreover, histone deacetylase 1 inhibitors
reversed the decrease in CD200R1 expression induced by LPS treatment.
Conclusions: CD200R1 expression decreases in microglial cells in the presence of a pro-inflammatory stimulus,
an effect that is regulated, at least in part, by C/EBPβ. Histone deacetylase 1 may mediate C/EBPβ inhibition of
CD200R1 expression, through a direct effect on C/EBPβ transcriptional activity and/or on chromatin structure.
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Background
In the presence of neuronal damage, microglial cells
acquire reactive phenotypes characterized by both mor-
phological and functional changes [1,2]. Microglial acti-
vation is a beneficial response, aimed at re-establishing
brain homeostasis and avoiding or minimizing neuronal
damage. However, reactive microglial cells produce sev-
eral factors (pro-inflammatory cytokines, reactive oxygen
and nitrogen species) that are typical of an inflammatory
response, with potential neurotoxic effects. Conse-
quently, the progression and resolution of microglial
activation need to be tightly controlled to avoid the
negative secondary effects of excessive or chronic micro-
glial reactivity [3].
In the normal brain, it has been postulated that micro-
glial reactivity is maintained under control by a series of
inhibitory mechanisms, in which signals arising from
neuronal cells are thought to play an important role
(reviewed in [4]). Alterations in these inhibitory signals
can result in microglial activation. In the presence of
brain tissue injury, microglial cells become activated
with a pro-inflammatory phenotype, suggesting that the
inhibitory mechanisms have been overcome. In the
present work, we focused on the study of one of these
inhibitory mechanisms: the CD200-CD200R1 ligand-
receptor system.
In the central nervous system (CNS), microglial cells
express CD200R1 and CD200 is constitutively expressed
mainly by neurons. Results from studies using CD200-
deficient mice suggest that this protein plays an
important role in the inhibition of the microglial pro-
inflammatory phenotype in the normal brain [5-8].
Results from in vitro studies also suggest a role for
CD200 in the control of microglial activation [9,10].
CD200 expression is decreased in the human brain of
patients with multiple sclerosis [11,12], and both CD200
and CD200R1 expression are decreased in the brain
of Alzheimer’s disease patients [13]. These observations
suggest that the CD200-CD200R1 inhibitory pathway
is altered in neurodegenerative disorders affecting the
human brain, in which glial activation/neuroinflammation
has been suggested to play a role in progression of
the neurodegeneration.
Little is known about the molecular mechanisms
involved in the regulation of CD200 and CD200R1
expression in physiological and pathological conditions
or on the mechanisms involved in the control of the
microglial pro-inflammatory response in the presence of
CD200R1 stimulation. In terms of CD200, Rosenblum
et al. [14] described the presence of functional DNA
binding sites for tumor suppressor protein p53, a critical
regulator of the apoptotic program, in the promoters of
the human and mouse CD200 gene and suggested a role
for CD200 in the regulation of apoptosis. Gorczynski’s
group detected a C/EBPβ binding site in the promoter of
the human CD200 gene that is required for the constitu-
tive expression of CD200 [15]. The same group also
reported that STAT1α, NF-κB p65 and IRF-1 play a role
in the regulation of CD200 inducible expression in
human T-cell lines [16]. Lyons et al. [9] showed that the
anti-inflammatory cytokine IL-4 induced an increase in
CD200 expression in rat neurons both in vivo and
in vitro. In contrast, molecular mechanisms controlling
the expression of CD200R1 have yet to be identified.
The CCAAT/enhancer binding protein β (C/EBPβ)
transcription factor is known to play a role in the control
of the expression of genes encoding pro-inflammatory
factors in reactive glial cells [17,18]. However, little is
known about its role in the regulation of genes encoding
anti-inflammatory factors. The objective of the present
work was to study whether C/EBPβ plays a role in the
regulation of CD200R1 expression in microglial cells.
Using glial cultures from wild-type and C/EBPβ-deficient
mice and BV2 cells (microglial cell line) overexpressing
C/EBPβ, we show that this transcription factor down-
regulates the expression of CD200R1 in reactive micro-
glial cells, an effect that is mediated, at least in part, by
histone deacetylase (HDAC) 1.
Methods
Animals
A colony of C/EBPβ+/- mice [19] on a C57BL/6-129 S6/
SvEv background was used to obtain C/EBPβ+/+ and C/
EBPβ-/- mixed glial cultures as previously described by
Straccia et al. [18]. Experiments were carried out in ac-
cordance with the Guidelines of the European Union
Council (86/609/EU) and following the Spanish regula-
tions (BOE 67/8509-12, 1988) for the use of laboratory
animals, and were approved by the Ethics and Scientific
Committees of Barcelona University and the Hospital
Clínic de Barcelona.
Cell cultures
Mixed glial cultures were obtained from pools of cere-
bral cortices of two- to four-day-old C57BL/6 wild-type
mice as described by Gresa-Arribas et al. [20]. In the
experiments with C/EBPβ-deficient mice, C/EBPβ+/+
and C/EBPβ-/- mixed glial cultures were obtained from
single 19-day-old embryos from C/EBPβ+/- progenitors
as described by Straccia et al. [18], due to the infertility
of C/EBPβ-/- females and a perinatal death rate of
approximately 50% for C/EBPβ-/- neonates. The culture
medium consisted of Dulbecco’s modified Eagle medium
(DMEM)/F-12 nutrient mixture (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
(FBS, Invitrogen), 0.1% penicillin-streptomycin (Invitro-
gen), and 0.5 mg/mL amphotericin B (FungizoneW, Invi-
trogen). Cells were maintained at 37°C in a 5% CO2
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humidified atmosphere. Medium was replaced every five
to sevendays.
Microglial cultures were prepared from 19 to 21 days
in vitro (DIV) mixed glial cultures using the mild trypsi-
nization method as previously described by our group
[21]. Briefly, the cultures were treated for 30 minutes
with 0.06% trypsin in the presence of 0.25 mM ethylene-
diamine tetraacetic acid (EDTA) and 0.5 mM Ca2+. This
resulted in the detachment of an intact layer of cells
containing virtually all the astrocytes, leaving a popula-
tion of firmly attached cells identified as >98% micro-
glia. The microglial cultures were used 24 hours after
isolation. Flow cytometry studies, qRT-PCR assays, quan-
titative chromatin immunoprecipitation (qChIP) and co-
immunoprecipitation experiments were performed using
primary mixed glial cultures due to the limited amount
of primary microglial cells usually obtained.
Astroglia-enriched cultures were obtained as described
by Saura et al. [22].
The mouse microglial cell line BV2 (generated from
primary mouse microglia transfected with a v-raf/v-myc
oncogene, Blasi et al. [23]) was kindly provided by Dr.
Elisabetta Blasi (Dip. Scienze Igienistiche, Microbiologiche
e Biostatistiche, Modena, Italy). Cells were cultured in Ros-
well Park Memorial Institute (RPMI)-1640 medium (Invi-
trogen), supplemented with 0.1% penicillin-streptomycin
(Invitrogen) and 10% heat-inactivated FBS. Cells were
maintained at 37°C in a 5% CO2 humidified atmosphere.
Stable clones overexpressing the C/EBPβ LAP isoform
were obtained. Briefly, BV2 cells were transfected with 1
μg pCDNA (empty vector) or pCDNA-LAP expression
plasmids (Dr. Steven Smale, UCLA, USA) using Lipofecta-
mine 2000 (Invitrogen). Positive clones were selected with
Zeocin™ (150 μg/mL) (Invitrogen) associated resistance.
Cells were seeded at a density of 5 × 104 cells/mL (1.6 × 104
cells/cm2) for immunocytochemistry and at 105 cells/mL
(2.4 × 106 cells/cm2) for protein and RNA extraction. One
day after seeding, the culture medium was replaced with
fresh RPMI medium, and the cells were used one day later.
Treatments
Cells were exposed to 100 ng/mL LPS from Escherichia
coli (026:B6, Sigma-Aldrich, St. Louis, MO, USA) for dif-
ferent lengths of time.
The HDAC inhibitors suberoylanilide hydroxamic acid
(SAHA) and MS-275 (Cayman Chemicals, Ann Arbor,
MI, USA) were used at 100 nM, 500 nM, 1 μM and
10 μM. They were added to the cultures one hour before
LPS treatment.
Immunocytochemistry
Cultured cells were fixed with 4% paraformaldehyde
in 0.1 M phosphate buffer (pH 7.4) for 20 minutes at
room temperature. Non-specific staining was blocked by
incubating cells with 10% normal donkey serum (Vector,
Peterborough, UK) in PBS containing 1% BSA for
20 minutes at room temperature. Cells were then incu-
bated overnight at 4°C with polyclonal goat anti-
CD200R1 (1:50, R&D, Abingdon, UK), alone or in
combination (mixed glial cultures) with monoclonal rat
anti-CD11b (1:200, Serotec, Oxford, UK) or polyclonal
rabbit anti-GFAP (1:1000, DAKO, Glostrub, DK) pri-
mary antibodies. After rinsing in PBS, cells were incu-
bated for one hour at room temperature with donkey
anti-goat ALEXA 488 (1:500) or ALEXA 594 (1:500),
alone or in combination with donkey anti-rat ALEXA
594 (1:500) or donkey anti-rabbit ALEXA 546 (1:1000)
secondary antibodies (Molecular Probes, Eugene, OR,
USA). In the case of mixed glial cultures, cells were per-
meated with 0.3% Triton X-100 in PBS containing 1%
BSA and 10% normal donkey serum for 20 minutes at
room temperature following fixation. Cell nuclei were
stained with Hoechst 33258 (Sigma). Microscopy images
were obtained with an Olympus IX70 microscope (Olym-
pus, Okoya, Japan) and a digital camera (CC-12, Olympus
Soft Imaging Solutions GmbH, Hamburg, Germany).
Isolation of total and nuclear proteins
Total protein extracts were obtained from mixed glial
cultures and BV2 cells. One well on a six-well plate was
used for each experimental condition. After a cold PBS
wash, cells were scraped off and recovered in 100 μL
of radioimmunoprecipitation assay (RIPA) buffer per
well (1% Igepal CA-630, 5 mg/mL sodium deoxycholate,
1 mg/mL SDS, protease inhibitor cocktail CompleteW -
Roche Diagnostics, Mannheim, Germany- in PBS).
Samples were sonicated, centrifuged for five minutes at
10,400 g and stored at -20°C. The amount of protein
was determined using the Lowry assay (Total protein kit
micro-Lowry, Sigma-Aldrich).
Western blot
Total protein extracts (50 μg) or immunoprecipitated
samples were denatured (120 mM Tris HCl pH 6.8, 10%
glycerol, 3% SDS, 20 mM dithiothreitol (DTT), and 0.4%
bromophenol blue, 100°C for five minutes) and sub-
jected to SDS-PAGE on a 10% polyacrylamide minigel,
together with a molecular weight marker (Fullrange
Rainbow Molecular Weight Marker, GE Healthcare, Lit-
tle Chalfont, UK), and transferred to a polyvinylidene
fluoride (PVDF) membrane (Millipore, Bedford, MA,
USA) for 90 minutes at 1 mA/cm2. The detection of the
proteins of interest was performed as described by
Gresa-Arribas et al. [20]. Monoclonal mouse anti-C
/EBPβ (1:500, Abcam, Cambridge, UK) and monoclonal
mouse anti-β-actin (1:50000, Sigma-Aldrich) were used
as primary antibodies. Horseradish peroxidase-labelled
goat anti-mouse was used as the secondary antibody
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(1:5000, Santa Cruz Biotechnology, Temecula, CA,
USA). The signal was developed with ECL-Plus (GE)
and images were obtained using a VersaDoc System
(Bio-Rad Laboratories, Hercules, CA, USA). The pixel
intensities of the immunoreactive bands were quanti-
fied using the % adjusted volume feature of Quantity
One 5.4.1 software (Bio-Rad Laboratories). Data are
expressed as the ratio between the intensity of the C/
EBPβ band and the loading control protein band (β-
actin).
Quantitative real-time PCR
CD200R1 and C/EBPβ mRNA expression was deter-
mined in primary glial cultures and BV2 cells six hours
after treatments. For isolation of total RNA, one well
from six-well culture plates was used per experimental
condition, with the exception of primary microglial cul-
tures, where one 75 cm2 flask was considered. Total
RNA was isolated using a High Pure RNA Isolation Kit
(Roche Diagnostics) and 1.5 μg of RNA for each condi-
tion was reverse transcribed with random primers using
Transcriptor Reverse Transcriptase (Roche Diagnostics).
Three nanograms of cDNA were used to perform quan-
titative real-time PCR. The following primers (Integrated
DNA Technology, IDT) were used: 5′-AGGAGGAT-
GAAATGCAGCCTTA-3′ (Forward) and 5′-TGCCTC-
CACCTTAGTCACAGTATC-3′ (Reverse) to amplify
mouse CD200R1 mRNA; 5′-AAGCTGAGCGACGAG-
TACAAGA-3′ (Forward) and 5′-GTCAGCTCCAGCA-
CCTTGTG-3′ (Reverse) for mouse C/EBPβ. For the
normalization of cycle threshold (Ct) values to an
endogenous control, the following primers were used:
5′-CAACGAGCGGTTCCGATG-3′ (Forward) and 5′-
GCCACAGGATTCCATACCCA-3′ (Reverse) for mouse
β-actin mRNA and 5′-GTAACCCGTTGAACCCCATT-3′
(Forward) and CCATCCAATCGGTAGTAGCG (Reverse)
for mouse Rn18s mRNA; β-actin and Rn18s mRNA
levels were not altered by cell treatment. Real-time PCR
was carried out using the IQ SYBR Green SuperMix
(Bio-Rad Laboratories) in 15 μL of final volume using an
iCycler MyIQ apparatus (Bio-Rad Laboratories). Samples
were run for 50 cycles (95°C for 15 seconds, 60°C for
30 seconds, and 72°C for 15 seconds). Relative gene
expression values were calculated using the comparative
Ct or ΔΔCt method [24] and iQ5 2.0 software (Bio-Rad
Laboratories). Ct values were corrected according to the
amplification efficiency of the respective primer pair
which was estimated from standard curves generated by
dilution of a cDNA pool.
Flow cytometry
CD200R1 protein expression was analyzed in control
and LPS-treated (24 hours) mixed glial cultures and BV2
cells. For each experimental condition, 5 × 105 cells
were collected and labelled with 10 μg/mL of polyclonal
goat anti-CD200R1 (R&D, Abingdon, UK) or goat
immunoglobulin G (IgG) (isotype control) in PBS for
20 minutes. Cells were washed once in PBS and incu-
bated with 1 μg/mL of donkey anti-goat ALEXA 488
secondary antibody (Molecular Probes) for 20 minutes.
Cell viability was evaluated by incubation with 10 μg/mL
propidium iodide (Molecular Probes). CD200R1 expres-
sion was analyzed with gating on live cells, using the BD
FACSCalibur™ platform (BD, Franklin Lakes, NJ, USA).
Quantitative chromatin immunoprecipitation (qChIP)
qChIP was performed as described by Straccia et al. [18]
with some modifications. Briefly, control and LPS-
treated (4 hours) primary mixed glial cultures or BV2
cells were cross-linked with formaldehyde (1% vol/vol
final concentration) and processed for chromatin extrac-
tion. Chromatin shearing resulted in fragments of
500 bp. An aliquot of chromatin sheared from each sam-
ple was separated as a loading control for the experi-
ment (input). The rest of the sample was processed for
chromatin immunoprecipitation (ChIP) using Dyna-
beadsW protein A (Invitrogen) and 2 μg of polyclonal
rabbit anti-C/EBPβ antibody (Santa Cruz Biotechnology)
or rabbit IgG (Santa Cruz Biotechnology) as the negative
control. DNA was isolated after the elimination of the
protein from the immunoprecipitated samples. Input
and ChIP samples were analyzed using real-time PCR
and SYBR green (Bio-Rad). Three microliters of input
DNA (diluted 1/50) and ChIP samples were amplified in
triplicate in 96-well plates using the MyIQ Bio-Rad Real
Time Detection System, as described in the section on
quantitative real-time PCR. The C/EBPβ binding site
in the IL-10 promoter was used as a positive control
(Liu et al., 2003). Match-1.0 (public version, BioBase)
and MatInspector (Genomatix) were used to identify C/
EBPβ consensus sequences in the 5,000 bp region up-
stream from the ATG translation start site of the
CD200R1 gene. The sequences for each amplified locus
and the primers used are shown in Table 1. Samples were
run for 45 cycles (95°C for 30 seconds, 62°C for one
minute, and 72°C for 30 seconds). For details regarding
data analysis see the section on quantitative real-time PCR.
Co-immunoprecipitation
Fifty microliters of DynabeadsW protein A (Invitrogen,
No.100.01D) were washed three times in PBS with 0.02%
Tween-20 and incubated for two hours at 4°C with 4 μg of
polyclonal rabbit anti-C/EBPβ (Santa Cruz Biotechnology),
or with 4 μg of rabbit IgG (Santa Cruz Biotechnology) as
negative control. Two hundred micrograms of protein
obtained from chromatin extracts from control and LPS-
treated (six hours) mixed glial cultures, as described above
in the qChIP protocol, were incubated overnight with the
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antibody-DynabeadsW complex at 40 rpm on a rotating
wheel at 4°C. The immuno complexes were pelleted using
a magnetic rack and washed three times with PBS. Beads
were removed from the samples by boiling in sample buffer
(120 mM Tris HCl pH 6.8, 10% glycerol, 3% SDS, 20 mM
DTT, and 0.4% bromophenol blue) for five minutes. Input
(1/5 dilution) and immunoprecipitated samples were sub-
jected to SDS-PAGE on a 10% polyacrylamide minigel.
Western blot analysis was conducted as described above
using monoclonal anti-HDAC1 antibody (1:2500, clone
2E10, Millipore) and monoclonal mouse anti-C/EBPβ anti-
body (1:500, Abcam). Samples immunoprecipitated with
isotype-DynabeadsW or incubated with unlabeled beads
were used as negative controls to demonstrate the specifi-
city of the signal obtained.
Data presentation and statistical analysis
The results are presented as the means + standard error
of the mean (SEM). Statistical analyses were performed
using one-way or two-way analysis of variance (ANOVA)
followed by the Bonferroni post-test when three or more
experimental groups were compared. Student’s t-test
was used to compare two experimental groups. Values
of P <0.05 were considered statistically significant.
Results
CD200R1 expression in microglial cells decreases in
response to the pro-inflammatory stimulus LPS
CD200R1 expression was determined by immunocyto-
chemistry in primary microglial cells in basal conditions
and 12, 24 and 48 hours after LPS treatment. CD200R1
immunolabeling was observed in control primary micro-
glial cells, defining the shape of the cells (Figure 1A). No
differences in immunolabeling were observed between con-
trol and treated microglia 12 hours after LPS (Figure 1B);
however, a marked decrease in labeling was observed
24 hours post-treatment (Figure 1C), and was still present
at 48 hours (Figure 1D). CD200R1 immunocytochemistry
was also evaluated in control and LPS-treated primary
mixed glial cultures, composed of astrocytes and microglia.
Basal expression of CD200R1 was observed in control cul-
tures (Figure 2A, C and D). CD200R1 immunolabeling in
the primary mixed glial cultures was localized in microglial
(Figure 2C, E, G and I) but not in astroglial cells
(Figure 2D, F, H and J). LPS treatment resulted in a de-
crease in CD200R1 labeling in the microglial cells
(Figure 2B). These results were confirmed at the level
of mRNA expression (Figure 3A). Basal expression of
CD200R1 mRNA was observed in control primary micro-
glial cultures and a decrease was observed in LPS-treated
cultures. No significant CD200R1 mRNA expression was
detected in astroglia-enriched cultures. We also detected a
decrease in CD200R1 protein expression in LPS-treated
primary mixed glial cultures via flow cytometry (Figure 3B).
The absence of C/EBPβ prevents the inhibition of
CD200R1 expression in response to LPS in microglial cells
To test whether C/EBPβ plays a role in the transcrip-
tional regulation of CD200R1, we analyzed CD200R1
Table 1 C/EBPβ putative binding sites in CD200R1 gene promoter and primers used in quantitative ChIP assay
Box Genomic localization with respect to ATG C/EBPβ consensus sequence Primers
1 −4028 −4014 tgATTTCacaaaat Fwd: 5′-CATTCCTGCTTCTGTCATGTG-3′
2 −3723 −3708 gtctttgGAAATtt Rev: 5′- GCCCTTACGCTTAACATCCA-3′
3 −2793 −2779 tgcttgaGCAATtt Fwd: 5′-CTTGGGAAAGTTGGGTTGTG-3′
4 −2546 −2529 ggcttggGAAAGtt Rev: 5′-TCCACACCATGGAGTTCATAA-3′
5 −1369 −1354 atgtttgGCAAGag Fwd: 5′-TGAGAGGTGGAGGAGGGTAA-3′
Rev: 5′-TCCTACCCCTGAGCAAAATG-3′
6 −450 −435 tggttagGAAATtt Fwd: 5′-TCTCACCATGGCATTTTCAA-3′
Rev: 5′-ATGCCCAAGACAGATGGATG-3′
Figure 1 CD200R1 immunostaining in primary microglial
cultures. (A) Control cultures and cultures treated with LPS for
12 hours (B), 24 hours (C) or 48 hours (D). Notice the decrease
observed at 24 hours, which was still detected at 48 hours following
LPS treatment. Cell nuclei are counterstained with Hoechst 33258.
Bar = 100 μm. LPS, lipopolysaccharide.
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mRNA expression in control and LPS-treated primary
mixed glial cultures of wild-type and C/EBPβ-deficient
mice using quantitative real-time PCR. We first con-
firmed that C/EBPβ protein expression was basally
detected in wild-type mixed glial cultures and increased
after LPS treatment, but was absent in C/EBPβ-deficient
cultures (Figure 4A). CD200R1 mRNA expression was
significantly lower in wild-type cultures six hours after
LPS treatment (Figure 4B). However, this decrease was
not observed in LPS-treated C/EBPβ-deficient cultures.
This effect occurred without any alteration in CD200R1
mRNA expression in basal conditions in the absence of
C/EBPβ.
C/EBPβ overexpression inhibits CD200R1 expression
In order to evaluate whether an increase in the expres-
sion of C/EBPβ was sufficient to inhibit CD200R1 gene
transcription in microglial cells, we overexpressed C/
EBPβ in BV2 cells. We first confirmed the expression of
CD200R1 in BV2 cells, and a decrease in this expression
after LPS treatment (Figure 5A). We then prepared
stable clones of BV2 overexpressing the C/EBPβ LAP
isoform (BV2-LAP cells), the most abundant C/EBPβ
isoform in glial cells. C/EBPβ overexpression was tested
using qRT-PCR and western blot, and significant
increases in C/EBPβ mRNA (Figure 5B) and C/EBPβ
LAP protein (Figure 5C) were observed in control BV2-
Figure 2 CD200R1 immunostaining in primary mixed glial
cultures. CD200R1 immunostaining in control primary mixed glial
cultures (A) and 24 hours after LPS treatment (B). The signal was
reduced in LPS-treated cultures. CD200R1 immunostaining (C and D)
is localized in anti-CD11b labelled cells (microglia) (E) but not in
anti-GFAP labelled cells (astrocytes) (F). G and H show Hoechst
33258 staining in the corresponding fields. I and J show merge
images. Bar = 100 μm in A-B and 50 μm in C-J. LPS,
lipopolysaccharide.
Figure 3 CD200R1 expression in glial cultures. (A) CD200R1
mRNA was detected in primary microglial cultures but not in
astroglia-enriched cultures using qRT-PCR. A clear decrease in
CD200R1 mRNA expression was detected in microglial cultures six
hours after LPS treatment. Bars are means + SEM of three cultures.
***P <0.001 versus C. Two-way ANOVA and Bonferroni post-test.
(B) Histogram plots showing CD200R1 staining in mixed glial
cultures by flow cytometry. A decrease was observed in cultures
treated with LPS for 24 hours (red line) when compared to control
cultures (green line). The black line shows control isotype staining.
The results are representative of three cultures. ANOVA, analysis of
variance; C, control; LPS, lipopolysaccharide; qRT-PCR, quantitative
reverse transcriptase polymerase chain reaction; SEM, standard
error of the mean.
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LAP cells in comparison to BV2-pCDNA clones (no
LAP overexpression). LPS treatment increased C/EBPβ
expression in both BV2-pCDNA and BV2-LAP cells.
C/EBPβ overexpression resulted in a significant
decrease in CD200R1 mRNA in untreated BV2-LAP cells
in comparison to untreated BV2-pCDNA cells (Figure 6A).
LPS induced a significant decrease in CD200R1 mRNA in
both types of clones. A decrease in CD200R1 protein was
also observed in BV2-LAP cells versus BV2-pCDNA cells
in untreated cultures via flow cytometry (Figure 6B-D).
A significant decrease in both the number of cells
expressing CD200R1 and the levels of CD200R1 expres-
sion was detected in control BV2-LAP cells versus BV2-
pCDNA cells.
C/EBPβ binds to the CD200R1 promoter in response to LPS
We next studied whether the effect of C/EBPβ on
CD200R1 regulation was due to a direct interaction with
the gene promoter. We first analyzed the 5,000 bp re-
gion upstream from the translation start site of the
CD200R1 gene using the bioinformatic softwares Match-
1.0 (public version, BioBase) and MatInspector (Geno-
matix), looking for putative C/EBPβ binding sites. Six
putative binding sites (herein referred to as box 1 to 6)
were identified, the positions and sequences of which
are indicated in Table 1.We then investigated whether
C/EBPβ could bind to these sites in a qChIP assay using
primary mixed glial cultures. Due to their proximity to
each other (less than 500 bp apart), it was impossible to
distinguish binding to box 1 and 2 or to box 3 and 4
using our experimental approach. We did not detect any
C/EBPβ binding to the CD200R1 gene promoter in
untreated primary mixed glial cultures. However,
Figure 4 CD200R1 expression in the absence of C/EBPβ.
(A) Western blot showing C/EBPβ protein expression in total
protein extracts of primary mixed glial cultures from control and
LPS-treated wild-type and C/EBPβ-deficient mice.
(B) CD200R1 mRNA expression in primary mixed glial cultures from
control and LPS-treated (six hours) wild-type and C/EBPβ-deficient
mice. The decrease in CD200R1 mRNA expression induced by LPS in
wild-type cultures was not observed in C/EBPβ-deficient cultures.
Bars are means + SEM of three to four independent experiments.
***P <0.001 versus C; ##P <0.01 versus wild type LPS-treated
cultures. Two-way ANOVA and Bonferroni post-test. ANOVA, analysis
of variance; C, control; C/EBPβ, CCAAT/enhancer binding protein β;
LPS, lipopolysaccharide; SEM, standard error of the mean.
Figure 5 CD200R1 and C/EBPβ expression in BV2 cells.
(A) CD200R1 immunostaining in control and LPS-treated BV2 cells.
A clear decrease was observed 24 hours after LPS treatment. Bar=50 μm.
(B)C/EBPβ mRNA and (C) western blot showing C/EBPβ protein
expression in control and LPS-treated (six hours) BV2-pCDNA and BV2-
LAP cell clones. Notice the strong increase in C/EBPβ expression in BV2-
LAP cells when compared to BV2-pCDNA cells. Bars are means+SEM of
three independent experiments. ***P <0.001 versus C and ###P< 0.001
versus the equivalent experimental condition in BV2-pCDNA cells; two-
way ANOVA and Bonferroni post-test. &P <0.05 and &&&P <0.001 versus
C; Student’s t-test. ANOVA, analysis of variance; C, control; C/EBPβ, CCAAT/
enhancer binding protein β; LPS, lipopolysaccharide; SEM, standard error
of the mean.
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significant binding of C/EBPβ to the CD200R1 gene pro-
moter was observed after LPS-treatment, but only at the
binding site closest to the ATG translation start site
(box 6) (Figure 7A).
Using our BV2 cell clones, we also assessed whether
C/EBPβ overexpression resulted in increased binding of
the transcription factor to the CD200R1 gene promoter.
As in mixed glial cultures, significant C/EBPβ binding to
the CD200R1 gene promoter in BV2-pCDNA cells was
only detected after LPS treatment, at the binding site
closest to the ATG translation start site (Figure 7B).
Nevertheless, significant C/EBPβ binding at the same
site was observed in untreated BV2-LAP cells. No differ-
ences in C/EBPβ binding were observed between control
and LPS-treated BV2-LAP cells.
C/EBPβ interacts with HDAC1 and determines the
inhibition of CD200R1 expression in microglial cells
To further elucidate the mechanism that underlies the
C/EBPβ-mediated inhibition of CD200R1 transcription
in microglial cells, we analyzed the possible involvement
of histone deacetylases. HDAC1 may mediate the effect
of C/EBPβ, given the role of this enzyme in histone
modifications linked to gene expression inactivation.
Using co-immunoprecipitation, we found that HDAC1
interacts with C/EBPβ mixed glial cultures treated with
LPS for six hours (Figure 8A). We then analyzed
whether HDAC1 was present in box 6 in the CD200R1
promoter using the qChIP assay. We detected binding of
HDAC1 in LPS-treated mixed glial cultures (Figure 8B),
suggesting that HDAC1 could interact with C/EBPβ to
control CD200R1 transcription. Finally, we also investi-
gated whether HDAC1 could play an active role in the
transcription of CD200R1, using the HDAC inhibitors
SAHA and MS-275. We observed that the inhibition of
CD200R1 mRNA expression detected in mixed glial cul-
tures after LPS treatment was partially reverted by both
HDAC inhibitors (Figure 8B and C).
Discussion
The results demonstrate that C/EBPβ is critically involved
in the regulation of CD200R1 gene expression in reac-
tive microglial cells. CD200R1 expression decreases in
microglia in response to the pro-inflammatory stimulus
Figure 6 CD200R1 expression in BV2 cells: effect of C/EBPβ overexpression. (A) CD200R1 mRNA expression in control and LPS-treated
(six hours) BV2-pCDNA and BV2-LAP cell clones. (B-D) CD200R1 protein in control and LPS-treated (24 hours) BV2-pCDNA and BV2-LAP cells
according to flow cytometry. (B) Histogram plots, representative of three independent experiments, showing CD200R1 staining in the BV2 cell
clones. (C) Quantification of CD200R1 positive cells and fluorescence intensity (D) in each experimental group. CD200R1 mRNA and protein
expression was lower in BV2-LAP cells than in BV2-pCDNA cells, due to an increase in both the number of CD200R1 positive cells and the level of
CD200R1 protein expression. Bars are means + SEM of three independent experiments. *P <0.05, **P <0.01 and ***P <0.001 versus C; ##P <0.01
and ###P <0.001 versus the equivalent experimental condition in BV2-pCDNA cells. Two-way ANOVA and Bonferroni post-test. ANOVA, analysis
of variance; C, control; C/EBPβ, CCAAT/enhancer binding protein β; LPS, lipopolysaccharide; SEM, standard error of the mean.
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LPS. However, this effect is not observed in the absence
of C/EBPβ and, in contrast, C/EBPβ overexpression
results in a decrease in CD200R1 expression in microglial
cells in basal conditions. We also show that, in response
to LPS, C/EBPβ binds the CD200R1 promoter and that
C/EBPβ interacts with HDAC1. These observations sug-
gest that the decrease in CD200R1 expression induced by
LPS in microglial cells is due, at least in part, to C/EBPβ
transcriptional regulation through a mechanism involving
histone deacetylation.
In the CNS, it has been suggested that the CD200-
CD200R1 interaction is one of the cell-contact mechan-
isms involved in the regulation of microglial activity by
neurons. Results from studies using CD200-deficient
mice and experimental models of inflammatory diseases
show that the CD200-CD200R1 interaction keeps micro-
glial cells in a quiescent/surveying phenotype in which
the pro-inflammatory response is inhibited, and that
microglial cells show increased reactivity when the
CD200-CD200R1 signal is impaired [6,8,25-28]. How-
ever, the mechanisms of inhibition of pro-inflammatory
activity triggered by CD200-CD200R1 signaling in
microglial cells have not been characterized. The signal
transduction pathways responsible for the inhibitory
effects of CD200R1 engagement have only been par-
tially described in mouse mast cells overexpressing
CD200R1 differentiated in vitro [29] and in the human
lymphoma cell line U937 [30]. On the other hand, lit-
tle is known about the molecular mechanisms regulat-
ing CD200 and CD200R1 expression in the CNS. We
observed that microglial CD200R1 expression decreases
in response to a pro-inflammatory stimulus. This effect
would result in decreased interaction between CD200
and CD200R1 in the presence of neurons, which in
turn would reduce the inhibitory input microglia re-
ceive from neurons in normal conditions. Conse-
quently, one of the mechanisms contributing to the
induction of a reactive microglia phenotype by pro-
inflammatory factors may be the down-regulation of in-
hibitory pathways such as CD200-CD200R1 signaling.
Glial activation results in significant changes in the ex-
pression of a large number of genes, among them those
encoding pro-inflammatory and anti-inflammatory
molecules. The expression of these genes must be tightly
regulated in order to orchestrate a controlled inflamma-
tory response lasting no longer than necessary. Various
transcription factors are involved in the regulation of
this expression (NF-κB, AP-1, STATs, PPARs, C/EBPs),
resulting in fine regulation of the inflammatory response
from start to finish. The transcriptional regulation of
CD200R1 has not been studied. We show here that C/
EBPβ is one of the transcription factors that is acti-
vated by pro-inflammatory stimuli playing a role in the
regulation of CD200R1 transcription. C/EBPβ does not
appear to play a role in the constitutive expression of
CD200R1 in microglial cells, given that we did not de-
tect any alteration in basal levels of CD200R1 mRNA
expression in control C/EBPβ-deficient glial cultures.
Nevertheless, increased levels of C/EBPβ down-regulate
CD200R1 expression, as observed in LPS-treated wild-
type glial cultures and not in C/EBPβ-deficient cul-
tures, as well as in BV2 cells overexpressing C/EBPβ.
These results suggest that C/EBPβ upregulation in re-
sponse to LPS contributes to the development of a
Figure 7 C/EBPβ binding to CD200R1 gene promoter in glial
cells. (A) Analysis of C/EBPβ binding to six putative binding sites of
the CD200R1 gene promoter in primary mixed glial cultures by
qChIP. Significant binding of C/EBPβ was only observed in box 6 in
LPS-treated cultures (four hours). Bars are means + SEM of three
independent experiments. ***P <0.001 versus IgG and C. One-way
ANOVA and Bonferroni post-test. (B) C/EBPβ binding to box 6 of the
CD200R1 gene promoter in BV2 pCDNA and BV2-LAP cells.
Significant binding of C/EBPβ was observed in LPS-treated (four
hours) BV2-pCDNA cells but also in control BV2-LAP cells. LPS
treatment did not induce a further increase in C/EBPβ binding in
LPS-treated BV2-LAP cells. Bars are means + SEM of three
independent experiments. ***P <0.001 versus IgG and C; ##P <0.01
versus the equivalent experimental condition in BV2-pCDNA cells.
Two-way ANOVA and Bonferroni post-test. ANOVA, analysis of
variance; C, control; C/EBPβ, CCAAT/enhancer binding protein β; IgG,
immunoglobulin G; LPS, lipopolysaccharide; qChIP, quantitative
chromatin immunoprecipitation; SEM, standard error of the mean.
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pro-inflammatory phenotype in microglial cells through
the inhibition of CD200R1 transcription.
In recent years, we have been studying the involve-
ment of C/EBPβ in glial activation. Using in vitro and
in vivo experimental approaches we have reported the
expression of C/EBPβ in astroglial and microglial cells,
and an increase in C/EBPβ expression in reactive glial
cells in response to pro-inflammatory stimuli and neur-
onal death [18,31-33]. This increase was further accentu-
ated in reactive microglial cells of G93A-SOD1 mice
(animal model of amyotrophic lateral sclerosis) and also
observed in microglial cells in the spinal cord of amyo-
trophic lateral sclerosis patients [32]. All these results
suggest an active role for C/EBPβ in glial activation. C/
EBP binding sites have been found in the promoters of
many genes encoding pro-inflammatory molecules [34-
36]. C/EBPβ regulates the LPS and LPS/IFNγ-induced
transcription of IL-6, IL-1β, TNF-α, COX-2 and iNOS
genes [18,37-41]. Interestingly, C/EBPβ deficiency has a
neuroprotective effect following ischemic [42] and exci-
totoxic injuries [17], as well as in an in vitro model of
neuroinflammation [18]. Nevertheless, little is known
about the involvement of C/EBPβ in the transcriptional
regulation of genes encoding anti-inflammatory mole-
cules, and even less so in CNS cells. Some authors have
reported a role for C/EBPβ in induction of the expres-
sion of the anti-inflammatory cytokine IL-10 in response
to LPS [43,44] or other stimuli [45,46] in macrophages.
These observations, together with the results of the present
study, suggest that, apart from its role in the expression of
pro-inflammatory molecules, C/EBPβ plays a role in the
control of the expression of anti-inflammatory molecules,
either activating or inhibiting their expression. This
Figure 8 Involvement of HDAC1 in the inhibition of CD200R1
expression by C/EBPβ. (A) Western blot showing HDAC1 (upper
image) and C/EBPβ (lower image) expression in nuclear protein
extracts from primary mixed glial cultures before (Input) and after
immunoprecipitation (IP) with anti-C/EBPβ antibody. HDAC1-C/EBPβ
co-immunoprecipitation was observed in LPS-treated cultures.
Samples immunoprecipitated with isotype or unlabeled beads were
used as controls to demonstrate the specificity of the signal
obtained. (B) Analysis of HDAC1 binding to C/EBPβ box 6 of
CD200R1 gene promoter by qChIP, showing interaction between
HDAC1 and C/EBPβ in LPS-treated cultures. Bars are means + SEM
of three independent experiments. ***P <0.001 versus IgG and C.
One-way ANOVA and Bonferroni post-test. Effect of the HDAC
inhibitors SAHA (C) and MS-275 (D) on CD200R1 mRNA expression
in control and LPS-treated primary mixed glial cultures. Both
attenuated LPS-induced inhibition of CD200R1 expression. Bars are
means + SEM of three independent experiments. *P <0.05, **P <0.01
and ***P <0.001 versus C; ##P <0.01 versus LPS. One-way ANOVA
and Bonferroni post-test. ANOVA, analysis of variance; C, control;
C/EBPβ, CCAAT/enhancer binding protein β; HDAC1, histone
deacetylase 1; IgG, immunoglobulin G; LPS, lipopolysaccharide;
qChIP, quantitative chromatin immunoprecipitation; SAHA,
suberoylanilide hydroxamic acid; SEM, standard error of the mean.
Dentesano et al. Journal of Neuroinflammation 2012, 9:165 Page 10 of 13
http://www.jneuroinflammation.com/content/9/1/165
constitutes an additional point of regulation of the in-
flammatory response in glial cells by C/EBPβ.
Several mechanisms may be responsible for the inhib-
ition of CD200R1 gene transcription by C/EBPβ. In vitro
studies using different cell types have shown that the
transactivating activity of C/EBPβ in the transcription of
target genes can be inhibited by post-translational modi-
fications such as sumoylation [47,48], phosphorylation
[49,50], methylation [51], deacetylation [52,53] and gly-
cosylation [54]. Interestingly, C/EBPβ has been shown
to associate with co-repressor complexes containing
HDACs in a gene promoter and inhibit gene transcrip-
tion [55-57]. The acetylation status of histones is a key
determinant of transcriptional activity (reviewed in [58]).
Histone acetyltransferases and HDACs are the enzymes
that reversibly catalyze histone acetylation. Recruitment
of histone acetyltransferases to gene promoters is usually
associated with the facilitation of gene transcription,
while that of HDACs is associated with gene repression.
However, it has been shown that a dynamic equilibrium
between acetylation and deacetylation is also necessary
for transcriptional activity. Using glial cultures, we found
that C/EBPβ interacts with HDAC1 and that HDAC1
binds the CD200R1 promoter at a C/EBPβ consensus
sequence following LPS treatment. These results, toge-
ther with the observation that HDAC inhibitors reverse
the LPS-induced reduction in CD200R1 expression, sug-
gest that HDAC1 plays a role in the C/EBPβ-mediated
repression of CD200R1 transcription observed in micro-
glial cells in response to LPS treatment. However, the
possible involvement of other HDACs cannot be ruled out.
This mechanism of transcriptional repression could involve
both histone deacetylation [55-57], resulting in changes in
chromatin structure and consequently in transcriptional
activity, and C/EBPβ deacetylation [52,53], resulting in
direct changes in transcriptional activity.
In recent years, several in vitro studies have shown
that HDAC inhibitors down-regulate pro-inflammatory
gene expression in macrophages and glial cells [59],
as well as in other cell types [60-62], in response to
inflammatory stimuli. HDAC inhibitors also attenuate
the pro-inflammatory response in experimental models
of cerebral ischemia [63] and endotoxemia in vivo [61].
Our results suggest that the anti-inflammatory effects of
HDAC inhibitors can be mediated, at least in part, by
potentiating the transcription of genes involved in keep-
ing the pro-inflammatory response under control, such
as CD200R1.
Conclusions
We describe, for the first time, a molecular mechanism
involved in the regulation of the expression of CD200R1
in microglial cells, in which the transcription factor
C/EBPβ plays a role. CD200R1 expression decreases in
microglial cells in response to a pro-inflammatory stimu-
lus, reducing the input that inhibits the microglial pro-
inflammatory phenotype in physiological conditions. We
show that C/EBPβ, in addition to its known role in the
regulation of the expression of pro-inflammatory genes,
can also negatively regulate the expression of genes
involved in the inhibition of the pro-inflammatory
response, such as CD200R1, thus contributing to the
development of the pro-inflammatory phenotype in
microglial cells. HDAC1 may mediate the inhibition of
CD200R1 expression by C/EBPβ through changes in chro-
matin structure and transcriptional activity.
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